Evidence map›Paper›PMID 35618302›Full record

ArticleThe Korean journal of internal medicine2022

Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study.

Soon Kyu Lee, Sung Won Lee, Hae Lim Lee, Hee Yeon Kim, Chang Wook Kim, Do Seon Song, U Im Chang, Jin Mo Yang, Sun Hong Yoo, Jung Hyun Kwon and 12 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The Korean journal of internal medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Observational
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 7 institutions in 2 countries.

Soon Kyu LeeDivision of Hepatology, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Sung Won LeeThe Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Hae Lim LeeThe Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Hee Yeon KimThe Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Chang Wook KimThe Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Do Seon SongThe Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
U Im ChangThe Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Jin Mo YangThe Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Sun Hong YooDivision of Hepatology, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Jung Hyun KwonDivision of Hepatology, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Soon Woo NamDivision of Hepatology, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Seok-Hwan KimThe Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Myeong Jun SongThe Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Jaejun LeeThe Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Hyun YangThe Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Si Hyun BaeThe Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Ji Won HanThe Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Heechul NamThe Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Pil Soo SungThe Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Jeong Won JangThe Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Jong Young ChoiThe Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Seung Kew YoonThe Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
The Catholic University of Korea Incheon St. Mary's Hospital · KRThe Catholic University of Korea Seoul St. Mary's Hospital · KRSt. Mary's Hospital · USThe Catholic University of Korea St. Vincent's Hospital · KRThe Catholic University of Korea Bucheon St. Mary's Hospital · KRThe Catholic University of Korea Daejeon St. Mary's Hospital · KRThe Catholic University of Korea Uijeongbu St. Mary's Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimsTo evaluate the efficacy and safety of ledipasvir/sofosbuvir (LDV/SOF) therapy in hepatitis C virus (HCV)-infected Korean patients in a real clinical setting.

methodsA total of 273 patients who received LDV/SOF therapy between May 2016 and February 2021 were consecutively enrolled and analyzed. A per-protocol analysis was performed to evaluate the virologic response.

resultsSeventy-five percent were infected with genotype 1, and 25% were infected with genotype 2. A hundred eightyone (66.3%) patients had chronic hepatitis, 74 (27.1%) had compensated cirrhosis, eight (2.9%) had decompensated cirrhosis, and 10 (3.7%) had undergone liver transplantation. Undetectable HCV RNA at week 4 was achieved in 90.2% (231/256) of patients, 99.2% (250/252) achieved the end of treatment response, and 98.1% (202/206) achieved sustained virologic response at 12 weeks post-treatment (SVR12). According to liver function, the SVR12 rates were 99.3% (135/136) in chronic hepatitis, 96.4% (53/55) in compensated cirrhosis, and 100% (6/6) in decompensated cirrhosis. The SVR12 rates according to the genotype were 98.2% (167/170) for genotype 1 and 97.2% (35/36) for genotype 2. An 8-week LDV/SOF treatment in treatment-naïve chronic hepatitis patients with HCV RNA < 6,000,000 IU/mL at baseline resulted in 100% (23/23) SVR12 rates. Overall, LDV/SOF was tolerated well, with a 0.7% (2/273) discontinuation rate due to adverse events that were unrelated to LDV/SOF.

conclusionLDV/SOF is effective and safe for treating HCV-infected Korean patients with high SVR12 rates.

Indexed as

Hepatitis CHepatitis C, ChronicAntiviral AgentsBenzimidazolesCohort StudiesFluorenesGenotypeHepacivirusHumansLiver CirrhosisRepublic of KoreaRNASofosbuvirTreatment OutcomeAntiviral AgentsBenzimidazolesFluorenesledipasvirledipasvir, sofosbuvir drug combinationRNASofosbuvirGenotypeHepatitis C virusLedipasvirSofosbuvirSustained virologic response

Identifiers

PMID35618302
PMCPMC9666263
OpenAlexW4281715618

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.